FDA expands approval of Vertex’ cystic fibrosis medicine to treat children aged 12 to <24 months

Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.

Prenatal exposure to violence increases toddlers’ aggressive behavior to their mothers

Babies whose mothers experience interpersonal violence during pregnancy are more likely to exhibit aggression and defiance toward their mothers in toddlerhood, according to new research by Laura Miller-Graff,assistant professor of psychology and peace studies, and Jennifer Burke Lefever, managing director of the William J. Shaw Center for Children and Families, both at the University of Notre Dame.